(Q36150781)

12 August 2017

1 reference

title

Treatment options in the management of ovarian cancer (English)

1 reference

12 August 2017

1 reference

Yoshihiro Kikuchi

1

1 reference

12 August 2017

Tsunekazu Kita

2

1 reference

12 August 2017

Masashi Takano

3

1 reference

12 August 2017

Kazuya Kudoh

4

1 reference

12 August 2017

Kenji Yamamoto

5

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

743-754

1 reference

Cancer survival increases in Europe, but international differences remain wide.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Management of recurrent ovarian cancer: evidence-based decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Synergistic interaction between topotecan and microtubule-interfering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Tumor angiogenesis: past, present and the near future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Antiangiogenic chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Angiozyme: a novel angiogenesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.5.743

21 January 2018

Identifiers

DOI

10.1517/14656566.6.5.743

1 reference

12 August 2017

1 reference